Premium
PHASE I/II STUDY OF UMBRALISIB (TGR‐1202) IN COMBINATION WITH UBLITUXIMAB (TG‐1101) AND PEMBROLIZUMAB IN PATIENTS WITH REL/REF CLL AND RICHTER'S TRANSFORMATION
Author(s) -
Mato A.R.,
Svoboda J.,
Luning Prak E.T.,
Schuster S.J.,
Tsao P.Y.,
Dorsey C.,
Sarmasti L.M.,
Becker P.S.,
Brander D.M.,
Nasta S.,
Landsburg D.J.,
King C.M.,
Morrigan B.,
Elwell J.,
Kennard K.,
Roeker L.,
Zelenetz A.D.,
Purdom M.,
Paskalis D.,
Sportelli P.,
Miskin H.P.,
Weiss M.S.,
Shadman M.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.79_2629
Subject(s) - pembrolizumab , medicine , neutropenia , immunology , immune system , immunotherapy , chemotherapy
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom